22nd May 2015 08:50
LONDON (Alliance News) - GlaxoSmithKline PLC Friday said it has submitted a regulatory application to the Japanese Ministry of Health, Labour and Welfare for mepolizumab as an add-on maintenance treatment for severe eosinophilic asthma, for patients who experience exacerbations on standard treatment.
Severe eosinophilic asthma is a sub-type of severe asthma where the over production of a type of white blood cell causes inflammation of the lungs.
Shares in GlaxoSmithKline are trading up 0.8% at 1,462.75 pence Friday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline